Chémobiologie
Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 5, Mai 2015
Chémobiologie
Page(s) 538 - 545
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20153105016
Publié en ligne 9 juin 2015
  1. Burnett G, Kennedy EP. The enzymatic phosphorylation of proteins. J Biol Chem 1954 ; 211 : 969–980. [PubMed]
  2. Guerrier P, Moreau M, Doree M. Hormonal control of meiosis in starfish: stimulation of protein phosphorylation induced by 1-methyladenine. Mol Cell Endocrinol 1977 ; 7 : 137–150. [CrossRef] [PubMed]
  3. Neant I, Guerrier P. 6-Dimethylaminopurine blocks starfish oocyte maturation by inhibiting a relevant protein kinase activity. Exp Cell Res 1988 ; 176 : 68–79. [CrossRef] [PubMed]
  4. Arion D, Meijer L, Brizuela L, Beach D. Cdc2 is a component of the M phase-specific histone H1 kinase: evidence for identity with MPF. Cell 1988 ; 55 : 371–378. [CrossRef]
  5. Azzi L, Meijer L, Ostvold AC, et al. Purification of a 15-kDa cdk4- and cdk5-binding protein. J Biol Chem 1994 ; 269 : 13279–88. [PubMed]
  6. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997 ; 243 : 527–536. [CrossRef] [PubMed]
  7. Bettayeb K, Oumata N, Echalier A, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008 ; 27 : 5797–5807. [CrossRef] [PubMed]
  8. Bach S, Knockaert M, Reinhardt J, et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005 ; 280 : 31208–31219. [CrossRef] [PubMed]
  9. Gray N, Detivaud L, Doerig C, Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem 1999 ; 6 : 859–875. [PubMed]
  10. Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 2003 ; 36 : 417–425. [CrossRef] [PubMed]
  11. Cohen P. Protein kinases: the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002 ; 1 : 309–315. [CrossRef] [PubMed]
  12. Mettey Y, Gompel M, Thomas V, et al. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem 2003 ; 46 : 222–236. [CrossRef] [PubMed]
  13. Doerig C, Meijer L, Mottram JC. Protein kinases as drug targets in parasitic protozoa. Trends Parasitol 2002 ; 18 : 366–371. [CrossRef] [PubMed]
  14. Jouan-Lanhouet S, Arshad MI, Piquet-Pellorce C, et al. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ 2012 ; 19 : 2003–2014. [CrossRef] [PubMed]
  15. Meijer L, Thunnissen AM, White AW, et al. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 2000 ; 7 : 51–63. [CrossRef] [PubMed]
  16. Corbel C, Haddoub R, Guiffant D, et al. Identification of potential cellular targets of aloisine A by affinity chromatography. Bioorg Med Chem 2009 ; 17 : 5572–5582. [CrossRef] [PubMed]
  17. Guiffant D, Tribouillard D, Gug F, et al. Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography. Biotechnol J 2007 ; 2 : 68–75. [CrossRef] [PubMed]
  18. Martins A, Vieira H, Gaspar H, Santos S. Marketed marine natural products in the pharmaceutical and cosmeceutical industries: tips for success. Mar Drugs 2014 ; 12 : 1066–1101. [CrossRef] [PubMed]
  19. Bharate SB, Sawant SD, Singh PP, Vishwakarma RA. Kinase inhibitors of marine origin. Chem Rev 2013 ; 113 : 6761–6815. [CrossRef] [PubMed]
  20. Kornprobst JM. lic>Encyclopedia of marine natural products. San Francisco : Wiley Blackwell, 2010 : 1680 p.
  21. Paul VJ, Ritson-Williams R, Sharp K. Marine chemical ecology in benthic environments. Nat Prod Rep 2011 ; 28 : 345–387. [CrossRef] [PubMed]
  22. Poulson KL, Sieg RD, Kubanek J. Chemical ecology of the marine plankton. Nat Prod Rep 2009 ; 26 : 729–745. [CrossRef] [PubMed]
  23. Burgaud G, Meslet-Cladière L, Barbier G, Edgcomb VP. Astonishing fungal diversity in deep-sea hydrothermal ecosystems: an untapped resource of biotechnological potential ? San Francisco : Wiley Blackwell, 2014.
  24. Gerwick. H, Roberts MA, Proteau PJ, Chen JL. Screening cultured marine microalgae for anticancer-type activity. J Appl Phycol 1994 ; 6 : 143–149. [CrossRef]
  25. Bhatnagar I, Kim SK. Marine antitumor drugs: status, shortfalls and strategies. Mar Drugs 2010 ; 8 : 2702–2720. [CrossRef] [PubMed]
  26. Poulsen SA, Davis RA, Keys TG. Screening a natural product-based combinatorial library using FTICR mass spectrometry. Bioorg Med Chem 2006 ; 14 : 510–515. [CrossRef] [PubMed]
  27. Vu H, Pham NB, Quinn RJ. Direct screening of natural product extracts using mass spectrometry. J Biomol Screen 2008 ; 13 : 265–275. [CrossRef] [PubMed]
  28. Abida H, Ruchaud S, Rios L, et al. Bioprospecting marine plankton. Mar Drugs 2013 ; 11 : 4594–4611. [CrossRef] [PubMed]
  29. Kornprobst JM. Médicaments de la mer : un état de la question. Biotendance 2010 ; 10 : 1–25.
  30. Prudent R, Soleilhac E, Barette C, et al. Les criblages phénotypiques ou comment faire d’une pierre deux coups. Med Sci (Paris) 2013 ; 29 : 897–905. [CrossRef] [EDP Sciences] [PubMed]
  31. Mahuteau-Betzer F. Chimiothèque Nationale : avancées et perspectives. Med Sci (Paris) 2015 ; 31 : 417–422. [CrossRef] [EDP Sciences] [PubMed]
  32. Da Silva P, Bendjeddou LZ, Meijer L. Recherche de substances naturelles à activité thérapeutique : George R. Pettit. Med Sci (Paris) 2014 ; 30 : 319–328. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.